Altre lingue Profound Medical Corp.

Azioni

PRN

CA74319B5027

Mercato chiuso - Toronto S.E. Altri mercati azionari 21:59:59 06/05/2024			Variaz. 5gg	Var. 1 gen.
10,04 ^CAD	-0,20%		-4,38%	-9,55%

13/03	Transcript : Profound Medical Corp. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
11/03	PROFOUND MEDICAL CORP. : Alliance Global Partners ribadisce il giudizio positivo sul titolo	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Profound Medical Says Clinical Evidence Points to Potential of Its TULSA Procedure as a Treatment for Prostate Cancer	06/05
Profound Medical Brief: Adds Clinical evidence Continues to highlight TULSA's "Ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH"	06/05
Profound Medical Brief: Says "Growing Body of Clinical Evidence" Points to Potential of Its TULSA Procedure "Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum"	06/05
Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum	06/05
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow	22/04
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04
Profound Medical Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Profound Medical Reports Q4 Net Loss of US$0.42 Per Share, Announces COO Appointment	07/03
Profound Medical Brief: Announcing promotion of Mathieu Burtnyk, from SVP Product Leader to Chief Operating Officer	07/03
Profound Medical Brief: Q4 2023 net loss was approximately US$8.9 million, or $0.42 per common share	07/03
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results	07/03
North American Morning Briefing : Powell Still in the Spotlight; ECB Rate Decision Looms	07/03
Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference	04/03
Profound Medical Collaborates With Siemens Healthineers to Expand Physician and Patient Access to the TULSA Procedure	27/02
Profound Medical Corp. Enters into A Non-Exclusive Collaboration with Siemens Healthineers	27/02
Profound Medical Brief: Entering Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure	27/02
Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure	27/02
Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow	15/02
Profound Medical Up 1.9% In US After Hours As Announces Non-Brokered Private Placement	16/01
Profound Medical Announces Non-Brokered Private Placement	16/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Profound Medical Corp.

Azioni

PRN

CA74319B5027

Altre lingue

Filtri